The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aeb9837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Noemia S Lima und 31 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, SARS-CoV-2, COVID-19, B-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Improving long-term protective immunity elicited by prime-boost vaccinations requires a deeper understanding of the immunologic outcomes of different vaccine platforms. Given the variety of platforms used to develop vaccines against SARS-CoV-2, we reasoned that SARS-CoV-2 offered an opportunity to compare vaccine platforms in humans. We used flow cytometry and single-cell transcriptomics to explore the B cell response to different homologous and heterologous vaccine regimens. We found that an adenovirus vector prime followed by a messenger RNA (mRNA) vaccine boost showed the greatest short-term B cell expansion and preferentially elicited an activated atypical B cell subset that was associated with antibody binding titers against spike protein. In contrast, an mRNA primary series followed by homologous boost induced a different activated B cell subset with more proliferative potential and high frequencies of a long-lived resting memory subset. Moreover, immunoglobulin A (IgA)–expressing memory B cells had more somatic hypermutations than the predominant IgG-expressing B cell population. This heterogeneity in vaccine-elicited B cell responses underscores the potential of tailoring vaccine regimens that combine different platforms to achieve potent and durable protection against infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Quantitative Virology and Evolution Unit, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Paleovirology Laboratory, Department of Biology, University of Oxford, Oxford OX1 2JD, UK.
- Baylor College of Medicine, Houston, TX 77030, USA.
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
ORCID-Profile: Noemia S Lima, Lauren McCormick, Samuel Li, Christian G Wake, Rahul Subramanian, Abby Spangler, William Catalano, I-Ting Teng, Kirsten E Lyke, Robert L Atmar, Meagan E Deming, Lisa A Jackson, Angela R Branche, Christina A Rostad, Christine M Johnston, Richard E Rupp, Angelica C Kottkamp, Rebecca C Brady, Martin Backer, Srilatha Edupuganti, Christine M Posavad, Paul C Roberts, Peter D Kwong, Sarah Andrews, Chaim A Schramm, Daniel C Douek
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- ASCRS Research Foundation
Zitieren
APA
Lima, N. S., McCormick, L., Li, S., Wake, C. G., Subramanian, R., Spangler, A., Pinto, Y., Catalano, W., Henry, A. R., Laboune, F., Teng, I. T., Lyke, K. E., Atmar, R. L., Deming, M. E., Jackson, L. A., Branche, A. R., Rostad, C. A., Martin, J. M., Johnston, C. M., …, & 21-0012 Study Group collaborators (2026). The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aeb9837
Vancouver
Lima NS, McCormick L, Li S, Wake CG, Subramanian R, Spangler A, et al. The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aeb9837
BibTeX
@article{Lima2026,
author = {Lima, Noemia S and McCormick, Lauren and Li, Samuel and Wake, Christian G and Subramanian, Rahul and Spangler, Abby and Pinto, Yoav and Catalano, William and Henry, Amy R and Laboune, Farida and Teng, I-Ting and Lyke, Kirsten E and Atmar, Robert L and Deming, Meagan E and Jackson, Lisa A and Branche, Angela R and Rostad, Christina A and Martin, Judith M and Johnston, Christine M and Rupp, Richard E and Kottkamp, Angelica C and Brady, Rebecca C and Backer, Martin and Edupuganti, Srilatha and 21-0012 Study Group, 21-0012 Study Group and Posavad, Christine M and Roberts, Paul C and Kwong, Peter D and Andrews, Sarah and Schramm, Chaim A and Douek, Daniel C and 21-0012 Study Group collaborators, 21-0012 Study Group collaborators},
title = {The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aeb9837}
}
EUVIMED